What Happened The Announcement Explained How We Got Here The FDA Category System and the 2023 Restriction Which Peptides Are Expected to Return and What the Science Says Why Physician Oversight Matters More After This Announcement, Not Less What Patients Should Do Now The Practical Roadmap What This Means for the Future of Longevity Medicine FAQ: About BPC-157 Peptide BPC-157 FDA Status 2026: What the RFK Reclassification Means for Patients | AgeMD BPC-157 FDA Status 2026: What the RFK Reclassification Means for Patients | AgeMD A guide to the 2026 FDA peptide reclassification what changed, which compounds are returning, and what patients should do next
Gene changes at the SN level are congruent with the hypothesis that dopaminergic neurons are affected by these proteins
Weight Loss Interest Public attention around GLP-1 receptor agonists and multi-agonist peptides has brought Retatrutide into focus for its potential weight-related effects
Nonsurgical treatment can be very effective, especially if theres no other damage to the shoulder
The TRIUMPH-CVOT readout will not arrive until 2028 or later, but it is the study that ultimately decides whether retatrutide is positioned as a full cardiometabolic compound rather than a weight-loss compound alone
Freezer storage at -20C in original packaging, keeping vials in their original sealed containers until needed